Cite

HARVARD Citation

    Morand, E. et al. (2023). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 401 (10381), pp. 1001-1010. [Online]. 
  
Back to record